Cue Biopharma to present new in vitro data for CUE-401

Cue Biopharma (CUE) announced that it will deliver a poster presentation on the company’s lead asset, CUE-401, at the World Immune Regulation Meeting, WIRM, being held March 11-14, 2026 in Davos, Switzerland. The presentation will include new in vitro data that demonstrate the therapeutic potential of CUE-401 to restore immune balance for the treatment of autoimmune and inflammatory diseases. Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein for the Treatment of Autoimmune and Inflammatory Diseases. In CD4+ T effector memory cells, CUE-401 showed TGF-beta-dependent suppression of proinflammatory cytokines, including Th1, Th2, and Th17 responses. In addition, the TGF-beta in CUE-401 prevented activated B cells from differentiating into plasma cells and limited antibody production. In natural killer cells, TGF-beta in CUE-401 counterbalanced the activating effects of interleukin-2, preventing proliferation and upregulation of proinflammatory cytokine production. Together, we believe these results demonstrate that CUE-401 has the potential to provide both short-term control of diverse inflammatory processes via TGF-beta, while also potentially providing durable long-term benefit through the induction and expansion of regulatory T cell responses